Headaches, injection site reactions, and pharyngitis were the most common adverse events associated with the biologic therapies dupilumab, omalizumab, mepolizumab, and reslizumab in the treatment of chronic rhinosinusitis (CRS) with nasal polyps.
A recent review shows that adverse events are common in clinical trials investigating biologic therapies for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), but further research is needed to address potential study limitations. Results were published in the American Journal of Otolaryngology–Head and Neck Medicine and Surgery.
As a chronic inflammatory condition that affects the nose and paranasal sinuses, CRSwNP is associated with a significant impact on health-related quality of life (QOL). Biologics have proved effective in the management of the condition, with a generally better safety profile compared with other treatment modalities such as endoscopic sinus surgery, but adverse events have been reported nonetheless.
“The management of CRSwNP is challenging due to disease recurrence and adverse effects. Although adverse events are not as common with these management modalities [biologics] as with the previous ones, they still exist and might constitute a burden that might impact the QOL of the treated patients,” the study authors wrote. “Some studies have reported that adverse events were common with [biologics]. However they were not specific and self-limited.”
Seeking to further assess safety and adverse events associated with different biological therapies for the management CRSwNP, they conducted a comprehensive systematic review of 13 studies, including 12 randomized controlled trials (RCTs) and one cross-sectional study, of which 6 were for dupilumab, 3 for omalizumab, 3 for mepolizumab, and only 1 investigated reslizumab. A total of 2282 patients with CRSwNP were included in the systematic review.
Overall, headaches, injection site reactions, and pharyngitis were the most common adverse events found in the investigated studies. Incidence of specific adverse events were cited for each biologic:
Researchers acknowledged that the review might be limited by the small number of included studies as some are based on data from previous investigations which added no actual value to the intended outcomes. The small sample size in some studies was also cited as a limitation of the study findings.
“Although the literature's current investigations indicate the safety of the biologic treatment modalities, further studies are needed as some uncertainty among the trials have been reported,” concluded researchers.
Reference
Aldajani A, Alroqi A, Alromaih S, Aloulah MO, Alsaleh S. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: a systematic review. Am J Otolaryngol. 2022;43(6):103615. doi:10.1016/j.amjoto.2022.103615
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
2 Commerce Drive
Cranbury, NJ 08512